Announcement

Collapse
No announcement yet.

Monsanto Facing GMO Lawsuit

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

  • Monsanto Facing GMO Lawsuit

    FluTrackers has routinely hosted threads about social injustices such as restrictions on the freedom of speech and the press, suppressive copyright infringement suits, inappropriate attempts for gene patenting, etc. This article describes a preemptive law suit against Monsanto by organic farmers whose crops may be contaminated by GMO genes in the future. In the past, Monsanto has sued some organic farmers for patent infringement in spite of the fact that the farmers neither wanted nor desired these GMO modifications in their seed stock.

    Monsanto Facing GMO Lawsuit
    Posted on April 11, 2011 by admin

    A class action suit has been filed by a group of plaintiffs connected with the organic/natural foods movement against the gene-splicing giant, Monsanto Corporation. The suit, filed March 29, 2011, in United States District Court, Southern District of New York, in Manhattan, seeks a declaratory judgment against Monsanto. If granted, the judgment will prohibit Monsanto from suing for patent infringement in the event that its patented genes, such as the glyphosate tolerance gene, should turn up in seeds or plants grown by organic or heirloom farmers.

    The suit was filed by the Public Patent foundation, or PUBPAT, a New York-based legal firm specializing in aspects of patent law pertaining to the public’s interest in such regulation. The suit was filed on behalf of about 60 plaintiffs, representing a broad spectrum of folks involved in the organic/pure foods movement. Trade organizations, like the Organic Seed Growers and Trade Association, Organic Crop Improvement Association International, Inc., and The Cornucopia Institute were named; such organizations in turn boast tens of thousands of members. Several seed companies are participating, including Adaptive Seeds, Baker Creek Heirloom Seed Co., Comstock-Ferre Seed Co., Fedco Seeds, Southern Exposure Seed Exchange, and numerous other companies. A number of individual farmers are also participating, including Wild Plum Farm, Montana, Jardin del Alma, New Mexico, Philadelphia Community Farm, Inc, and others.

    The suit alleges that Monsanto’s aggressive tactics have, in the past, resulted in undue hardships on small operations who inadvertently experienced contamination from GMO crops, especially those containing the glyphosate tolerance gene (commonly known as the “Roundup-ready” gene)as exemplified in the well-known Percy Schmeiser case. In that case, Schmeiser, a canola farmer, was accused of patent infringement because Monsanto-owned genes turned up in his fields, in the absence of any license from Monsanto.

    In a press release, PUBPAT said, “The organic plaintiffs were forced to sue preemptively to protect themselves from being accused of patent infringement should their crops ever become contaminated by Monsanto’s genetically modified seed.” If the plaintiffs prevail, future situations like the Schmeiser case would not happen, at least in the United States, as Monsanto wouldn’t be able to sue when the intention of the farmer was to raise GMO-free crops. (The Schmeiser cases happened in Canada; this ruling would affect only American farms.)

    PUBPAT cited four grounds for the suit, any one of which, if proved, should be sufficient to cause the court to issue the declaratory judgment.

    1.) Monsanto’s patents are invalid
    By law, patents must be new, non-obvious and useful. The suit asserts that not only are GMO’s not useful, but they may actually be harmful to public health, the environment and society as a whole. Moreover, they are obvious since they derive from gene sequencing. The complaint cites a number of studies and cases to support this claim.

    2.) Monsanto’s patents are not infringed
    Since there is no intention on the part of contaminated farmers to infringe patents, there can be no patent infringement. Instead, contamination is in fact a trespass, causing damage to the affected farmers. The complaint contends that it is “perverse” that farmers whose crops have been contaminated should also be subject to litigation for patent infringement.

    3.) Monsanto’s patents are not enforceable
    If both previous arguments fail and patents are still admitted by the judge as being valid and infringed, PUBPAT intends to demonstrate that they are not enforceable because they are being misused to gain undue control over the market.

    4.) Monsanto is not entitled to any remedy
    Since the farmers in the class are seeking to produce only GMO-free crops, and GMO contamination destroys the value of such crops, Monsanto has not lost revenue due solely to the production of the contaminated crops. Consequently, it is not entitled to damages.

    To be successful, the plaintiffs need only successfully prove any one of the four bases for the suit. Monsanto, on the other hand, must successfully refute all four of the claims to prove its case.

    The suit has received widespread attention in the media and on the Internet, and has caused a sensation among pure food advocates and consumers, many of whom view the suit as yet another David-and-Goliath situation.

    http://novel-infectious-diseases.blogspot.com/

  • #2
    Re: Monsanto Facing GMO Lawsuit

    This is all part and parcel of the problem in the US with the boundaries in copyright and patent law. Were these laws capable of only having an effect within the US then I would not care but of course they don’t. In Europe we decided to let the individual make the choice as to whether they wanted to consume GMO products but this is of course not possible. Despite industry claims to the contrary FluTrackers regulars are going to be well aware that genes tend not to stay where you, or nature, put them. The techniques (also subject to dubious patents) used to insert genes into new locations are already purloined from nature and quite capable of re-redistributing implanted nucleic acid sequences in vivo. There is a lot more to genetic material redistribution than Mendel could possibly have imagined and probably a lot more than our current level of understanding is aware of.

    The troubles with Indonesia re biological sample sharing, with Mexico re patents on local/wild Maize strains, with the EU on GMO labelling/pollution, with India/Thailand and other developing economies on generic drugs etc are all manifestations of the same problem, namely a very different view in where patent law boundaries should be drawn between corporate America and everyone else.

    On the copyright side we have the likes of Righthaven and the ‘Disney’ law.

    While the financial aspects may be resolvable overtime the control of genetic material releases out of the lab and into the environment are a bigger problem and beyond the deep pockets of Monsanto to correct if one of these gambles takes an unforeseen turn like the well intentioned introduction of rabbits in Australia.

    Edit:
    I would also like to recommend this Atlantic article which Sharon linked to earlier looking at <!--[if gte mso 9]><xml> <w:WordDocument> <w:View>Normal</w:View> <w:Zoom>0</w:Zoom> <w:Compatibility> <w:BreakWrappedTables/> <w:SnapToGridInCell/> <w:WrapTextWithPunct/> <w:UseAsianBreakRules/> </w:Compatibility> <w:BrowserLevel>MicrosoftInternetExplorer4</w:BrowserLevel> </w:WordDocument> </xml><![endif]--><!--[if gte mso 10]> <style> /* Style Definitions */ table.MsoNormalTable {mso-style-name:"Table Normal"; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-parent:""; mso-padding-alt:0cm 5.4pt 0cm 5.4pt; mso-para-margin:0cm; mso-para-margin-bottom:.0001pt; mso-pagination:widow-orphan; font-size:10.0pt; font-family:"Times New Roman";} </style> <![endif]-->Association of Molecular Pathology, et al. v United States Patent and Trademark Office, et al
    Theses quotes from that article sum up the basic problem nicely.

    The first is from <!--[if gte mso 9]><xml> <w:WordDocument> <w:View>Normal</w:View> <w:Zoom>0</w:Zoom> <w:Compatibility> <w:BreakWrappedTables/> <w:SnapToGridInCell/> <w:WrapTextWithPunct/> <w:UseAsianBreakRules/> </w:Compatibility> <w:BrowserLevel>MicrosoftInternetExplorer4</w:BrowserLevel> </w:WordDocument> </xml><![endif]--><!--[if gte mso 10]> <style> /* Style Definitions */ table.MsoNormalTable {mso-style-name:"Table Normal"; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-parent:""; mso-padding-alt:0cm 5.4pt 0cm 5.4pt; mso-para-margin:0cm; mso-para-margin-bottom:.0001pt; mso-pagination:widow-orphan; font-size:10.0pt; font-family:"Times New Roman";} </style> <![endif]-->Gary Cohen who is Vice President of Bioethics, Law & Policy at Foundation Medicine
    <!--[if gte mso 9]><xml> <w:WordDocument> <w:View>Normal</w:View> <w:Zoom>0</w:Zoom> <w:Compatibility> <w:BreakWrappedTables/> <w:SnapToGridInCell/> <w:WrapTextWithPunct/> <w:UseAsianBreakRules/> </w:Compatibility> <w:BrowserLevel>MicrosoftInternetExplorer4</w:BrowserLevel> </w:WordDocument> </xml><![endif]--><!--[if gte mso 10]> <style> /* Style Definitions */ table.MsoNormalTable {mso-style-name:"Table Normal"; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-parent:""; mso-padding-alt:0cm 5.4pt 0cm 5.4pt; mso-para-margin:0cm; mso-para-margin-bottom:.0001pt; mso-pagination:widow-orphan; font-size:10.0pt; font-family:"Times New Roman";} </style> <![endif]-->
    We've been accustomed to thinking of DNA as a molecule, a chemical entity (which, of course, it is). But in this more sophisticated era, we understand that DNA is not "just" a molecule; its an information-carrying molecule. Genes are better thought of as packets of information, not mere molecules, Judge Sweet reasoned. This reasoning is key to his decision -- because the information encoded by a gene is the same, whether its sitting amongst its natural neighbor genes, or in isolated form. That's why researchers want to isolate genes -- because they are useful in all sorts of ways, but only because the isolated form contains the same genetic instructions as the naturally-occuring form. Using this information paradigm, the judge reasoned that "isolation" does not render a naturally-occurring gene something novel, something patentable.
    The second is from the Justice Department's court filings prior to Judgment.
    The district court correctly held, however, that genomic DNA that has merely been isolated from the human body, without further alteration or manipulation, is not patent-eligible.... The chemical structure of native human genes is a product of nature, and it is no less a product of nature when that structure is "isolated" from its natural environment than are cotton fibers that have been separated from cotton seeds or coal that has been extracted from the earth.
    Which is significantly at odds with the Patent Office's position. Battle resumes tomorrow.

    Again - as in newspapers vs new media - this is a business model problem. We need news organisations and pharmaceutical companies to be able to gather news and develop diagnostic tests/medicines for which they need funding the question is, 'Is this the way to pay them?'.

    Edit2:
    Link to the .mp3 of the oral argument.
    I think the argument @ 44:30 is the clincher. This is never going to be the end this is so critical to the patent law boundary this train is going to SCOTUS eventually. After which Congress may or may not get involved.

    Comment

    Working...
    X